XPhyto Therapeutics Corp.
VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / December 15, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to provide an update on the development of its fast-dissolving CBD oral strips. With significant complexities involved in the planning and preparation for the pending human pilot study, the Company is pleased to announce that its European human CBD bioavailability study will commence in January 2022.
Prof. Dr. Beckert said, "the clinical trial of our CBD product is aiming to demonstrate the efficient and precise dosing of the treatment. If successful, this could make a significant difference to Epilepsy patients and we are excited to commence the trial next year."
XPhyto is developing a hybrid-generic CBD prescription drug formulation that employs the Company's proprietary oral dissolvable ("ODF") platform to deliver precise and efficient CBD dosages for the treatment of certain forms of childhood Epilepsy.
The US Food & Drug Administration (FDA) and European Medicines Agency (EMA) have approved CBD based medical products from other companies for the treatment of severe childhood forms of Epilepsy, including Dravet syndrome and Lennox-Gastaut syndrome. The currently approved and registered formulation of CBD is a lipophilic solution in sesame oil with a standard dosage of 750 mg/day. Due to low bioavailability (approximately 5%) the formulation could be considered highly inefficient compared to the XPhyto ODF platform.
For the purpose of carrying out XPhyto's clinical study, the following important and necessary items have been completed or received: Product Development Report, Investigational Medicinal Product Dossier, Permit for Clinical Study, manufacture of clinical product samples; Product Specification File; monitoring agreement; and Import Authorization to the location of the FDA-inspected Clinical Research Center. Pending success in the CBD pilot study, the Company expects to carry out a pivotal clinical study in 2H of 2022.
The Company's CBD-based Epilepsy treatment program is one of several dissolvable oral drug delivery programs. Oral thin film drug delivery is a large and growing international industry which provides an alternative to conventional solid and liquid oral dosage forms. Transparency Market Research estimates that the global market for thin film drug manufacturing will be worth US$15.98 billion by 2024, rising at a 9.0% CAGR between 2019 and 2024. XPhyto's additional oral thin film drug delivery programs include both cannabinoid and non-cannabinoid products for pain, neurology, and infectious disease. The Cannabidiol Market revenue is estimated to be worth over US$89 billion by 2026 according to Global Market Insights Inc.
Executive management of XPhyto's drug formulation business is led by Prof. Dr. Beckert, managing director of Vektor Pharma TF GmbH. Prof Dr. Beckert is a German-based scientist and experienced corporate executive who is leading XPhyto's drug formulation and diagnostics operations.
About XPhyto Therapeutics Corp.
XPhyto Therapeutics Corp. is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.
XPhyto Therapeutics Corp.
Hugh Rogers, CEO and Director
Investor Inquiries:
Mr. Knox Henderson
T: 604-551-2360
E: info@xphyto.com
Forward looking statements
This news release includes statements containing forward-looking information within the meaning of applicable Canadian securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "develop", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "potential", "propose" and other similar words, or statements that certain events or conditions "may" or "will" occur, and in this release include the statement regarding the Company's goal of building a successful diagnostic, drug delivery, and medical cannabis company. Forward-looking statements are only predictions based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements, including: that the Company may not succeed in developing a commercial product; that the sale of products may not be a viable business; that the Company may be unable to scale its business; product liability risks; product regulatory risk; general economic conditions; adverse industry events; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; currency risks; competition; international risks; and other risks beyond the Company's control. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this news release.
SOURCE: XPhyto Therapeutics Corp.
View source version on accesswire.com:
https://www.accesswire.com/677717/XPhyto-Epilepsy-Clinical-Trial-Planned-in-2022-with-Its-Proprietary-Fast-Dissolving-CBD-Oral-Strips
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
From NASA to Your Boardroom: Freelancer Opens 85-Million-Mind Innovation Engine to All Enterprises23.1.2026 14:00:00 CET | Press release
The platform that slashed NASA's R&D costs and compressed three-day computations into one hour is now available to any organisation Previous challenge winner's spacecraft solution is bound for space What do you do when your toughest technical problem stumps every expert in your building? If you're NASA, you throw it open to 85 million minds across 140 countries. Starting today, any company can do the same. SAN FRANCISCO, CA / ACCESS Newswire / January 23, 2026 / Freelancer (ASX:FLN) announced the global launch of its Moonshot Innovation Program, opening the breakthrough platform that has delivered over 20,000 solutions to NASA, NIH, and the CDC to enterprises worldwide. The same system that helped NASA save 80-99% on R&D costs, compressed Bureau of Reclamation river modelling from 72 hours to 60 minutes, and generated 54 genome therapy breakthroughs for NIH is now available to any organization with a problem that traditional consulting can't crack. The results speak louder than any pit
Datavault AI Inc. Completes Acquisition of API Media23.1.2026 12:00:00 CET | Press release
Technology Provider API Media extends Datavault AI and the patented ADIO Technology to the Live Outdoor Event Market PHILADELPHIA, PA / ACCESS Newswire / January 23, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, digital engagement and real‑world asset tokenization technologies, today announced that it has closed its previously announced acquisition of API Media Innovation Inc ("API"), a provider of media infrastructure and event technology solutions. API, headquartered in New Jersey, has a decades-long tradition of providing innovative audio and visual technologies to the world of media, sports, and entertainment. API's clients include some of the most prestigious and sought-after sports venues and events, made possible through a dedicated and customer-first culture cultivated over decades. "We are pleased to complete this acquisition, which marks a decisive next step in our strategy to scale Datavault AI's propr
Aviwell Closes €11 Million Series A Investment Round to Scale AI‑Driven Microbiota Platform for Sustainable Animal Nutrition23.1.2026 06:01:00 CET | Press release
TOULOUSE, FRANCE AND BOSTON, MA / ACCESS Newswire / January 23, 2026 / Aviwell SAS, a deep‑tech animal nutrition company headquartered in Toulouse, today announced the successful completion of a €11 million Series A investment round, welcoming three new investors: Blue Revolution Fund (BRF), Blast.Club, and SWEN Capital Partners. The financing will support Aviwell's next phase of growth as the company scales its AI‑driven microbiome discovery and development platform and advances native, nature‑based biological solutions for global agri‑food markets, initially focused on poultry and aquaculture. Built on decades of research pioneered by Aviwell's co‑Founder, Prof. Remy BURCELIN, into how naturally occurring bacterial ecologies administered early in life can have a durable impact on animal growth, health, and resilience, Aviwell has developed Aneto™, an AI‑powered microbiome discovery platform. Aneto™ identifies specific molecular mechanisms - modes of action - that enable the selection
Loar Holdings Inc. Announces the Acquisition of Harper Engineering Company22.1.2026 14:30:00 CET | Press release
WHITE PLAINS, NEW YORK / ACCESS Newswire / January 22, 2026 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today that it has completed the acquisition of Harper Engineering Company ("Harper") for cash consideration of $250 million. Founded in 1968 by O.J. Harper, Harper Engineering is a leading manufacturer of mechanically engineered devices for aircraft interiors. The company holds a proprietary portfolio of latching and securing mechanisms used across multiple leading commercial aerospace platforms. Known for exceptional quality and on-time delivery, Harper consistently earns top recognition from its original equipment and aftermarket customers. The company employs approximately eighty-five team members across two facilities in the Seattle, Washington area. "Harper maintains well-established line-fit positions on several leading in-production aircraft, positioning the business to benefit from near-term growth in commercial build rates," said Dirkson Charles, Chief Executive Offi
GoodData Announces Launch of MCP Server to Let AI Execute Analytics End-to-End21.1.2026 10:00:00 CET | Press release
Combining MCP, analytics-as-code, and LLMs to automate analytics execution at software speed SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 21, 2026 / GoodData, a leader in AI analytics and decision intelligence, today announced the public launch of its MCP Server. As organisations adopt AI in analytics, most tools remain limited to query generation, leaving teams to manually manage metrics, dashboards and business logic. MCP Server moves AI beyond analysis, enabling governed, end-to-end analytics execution and delivering 10-50x faster time to value. The MCP Server is designed for AI developers, and BI and data teams who want to build and manage analytics faster with AI. It allows AI to build and operate analytics in the same way a skilled human team would, but faster and without operational bottlenecks. Using the Model Context Protocol (MCP), AI agents and large language models (LLMs) can connect directly to GoodData and execute analytics across the full lifecycle. They can wor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom